Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis’.

The above information is a part of company’s filings submitted to BSE.